Thyroid cancer test kit THYROCAN™

oncologyfor precision medicinefor BRAF mutations

Thyroid cancer develops from the thyroid gland. Although thyroid cancers are curable with treatments such as surgery, hormone therapy, radioactive iodine and the most common types of thyroid cancer, papillary and follicular subtypes by external radiation therapy. One-tenth of such patients will have recurrent disease. However, medullary thyroid cancer has a worse prognosis and may also be genetically inherited. Anaplastic thyroid cancer is the most aggressive form of thyroid cancer. Several targeted therapies with kinase inhibitors have been approved to treat non-responsive radioactive iodine patients with differentiated papillary and follicular thyroid cancers as well as medullary and anaplastic thyroid cancer patients.  Detects driver mutations in thyroid cancer such as BRAF, RET and RAS to inform targeted therapy options Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers Assesses genetic predisposition for thyroid cancer  WHO IS IT FOR Thyroid cancer patients seeking precision medicine  Differentiated papillary and follicular thyroid cancer patients resistant to radioactive iodine therapy  Medullary and anaplastic thyroid cancer patients  SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)